<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102994</url>
  </required_header>
  <id_info>
    <org_study_id>2021-VRL-diagnosis</org_study_id>
    <nct_id>NCT05102994</nct_id>
  </id_info>
  <brief_title>Mutation Detection for VRL</brief_title>
  <official_title>The Diagnostic Value of Mutation Detection for VRL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitreoretinal lymphoma (VRL) is a rare but aggressive masquerade syndrome, which would be&#xD;
      easily confused with uveitis. The diagnostic gold standard remains the pathologic examination&#xD;
      of ocular specimen with invasiveness and low sensitivity. To improve the safety and accuracy&#xD;
      of VRL diagnosis, alternative techniques using intraocular fluid (IOF) samples are emerging.&#xD;
      In this study, we aimed to test the diagnostic value of mutation analysis for VRL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      chest CT, urinalysis, kidney, and liver function were routinely checked.&#xD;
&#xD;
      IL-10/IL-6 ratio, genetic mutation analysis and samples were IGH gene rearrangements were&#xD;
      reviewed and analyzed retrospectively.&#xD;
&#xD;
      The diagnoses were identified after careful evaluation of treatment effects in follow-up. The&#xD;
      diagnostic value including sensitivity, specificity, positive and negative predictive values,&#xD;
      and test efficiency of genetic mutation analysis in diagnosing VRL were analyzed.&#xD;
&#xD;
      Furthermore, a validation group of patients including VRL and uveitis was selected to&#xD;
      validate the diagnostic value of mutation analysis in the diagnosis of VRL. All the patients&#xD;
      signed an informed consent and institutional review board approval was obtained. The study&#xD;
      was performed in accordance with the tenets of the Declaration of Helsinki.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the result of mutation test</measure>
    <time_frame>at baseline, before treatment</time_frame>
    <description>any mutation detect in intraocular fluild recorded as ctDNA+</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vitreoretinal Lymphoma</condition>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>VRL patients group</arm_group_label>
    <description>Presenting clinical features suggestive for VRL with positive finding in laboratory exam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uveitis group</arm_group_label>
    <description>Even if characterized as clinical features of presumed VRL, no positive laboratory investigations for lymphoma and well response to IMT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>mutation test</intervention_name>
    <description>detect the tumor-related mutation in introcular fluid</description>
    <arm_group_label>VRL patients group</arm_group_label>
    <arm_group_label>uveitis group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Combined ocular manifestations with the results of pathology, IL-10/IL-6 ratio, IGH gene&#xD;
      rearrangements and patients' response to treatments, patients abtained clear diagnosis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        suspected VRL or uveitis patients attending to our clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suspected VRL patients who had intraocular fluid for mutation test. And got a clear&#xD;
             diagnose of VRL or uveitis afther having dianostic tests and follow-up treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  suspected VRL patients who lost in follow-up without a definitive diagnose, or whoever&#xD;
             reluctance to participate our study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan D Liang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Vitreoretinal lymphoma</keyword>
  <keyword>Uveitis</keyword>
  <keyword>intraocular fluid</keyword>
  <keyword>mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

